Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data

benzinga.com/markets/large-cap/25/09/47621785/merck-advances-childhood-pneumococcal-care-with-promising-vaccine-data

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference.
The trial evaluated the safety,…

This story appeared on benzinga.com, 2025-09-11 14:23:43.
The Entire Business World on a Single Page. Free to Use →